Douglas J. Manion's most recent trade in Aclaris Therapeutics Inc was a trade of 27,000 Common Stock done . Disclosure was reported to the exchange on Jan. 1, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | Douglas Manion J. | Director, Pres and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 27,000 | 50,938 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | J. Manion Douglas | Director, Pres and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 27,000 | 81,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Douglas Manion J. | Director, Pres and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.05 per share. | 01 Jan 2024 | 9,125 | 41,813 (0%) | 0% | 1.0 | 9,581 | Common Stock |
| Aclaris Therapeutics Inc | Douglas J. Manion | Director, Pres and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2023 | 15,575 | 28,375 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Douglas J. Manion | Director, Pres and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2023 | 15,575 | 46,725 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Douglas J. Manion | Director, Pres and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.81 per share. | 01 Aug 2023 | 4,437 | 23,938 (0%) | 0% | 9.8 | 43,527 | Common Stock |
| Aclaris Therapeutics Inc | Douglas J. Manion | Director, Pres and CEO | Purchase of securities on an exchange or from another person at price $ 7.86 per share. | 17 Mar 2023 | 6,300 | 12,800 (0%) | 0% | 7.9 | 49,532 | Common Stock |
| Aclaris Therapeutics Inc | Douglas J. Manion | Director, Pres and CEO | Purchase of securities on an exchange or from another person at price $ 7.74 per share. | 09 Mar 2023 | 6,500 | 6,500 (0%) | 0% | 7.7 | 50,278 | Common Stock |
| Aclaris Therapeutics Inc | Douglas J. Manion | Director, Pres and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 378,000 | 378,000 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Douglas J. Manion | Director, Pres and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 108,000 | 108,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Douglas J. Manion | Pres and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 217,800 | 217,800 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Douglas J. Manion | Pres and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 62,300 | 62,300 | - | - | Restricted Stock Units |